Bernadette Tansey
Bernadette Tansey has covered biotechnology, business, law, environment, and government as a Bay area journalist. She was a biotechnology reporter for the San Francisco Chronicle, where she also tracked the emerging fields of nanotechnology and synthetic biology. Bernadette studied neurobiology as a journalism fellow at Harvard Medical School, and learned about advances in medical devices during a National Press Club fellowship at UC San Diego. She was an environmental reporting fellow with the Institutes for Journalism and Natural Resources.
At the Stanford University Graduate School of Business, Bernadette served as a staff writing coach for an academic program in logic and communication for MBA students. She taught business journalism and reporting at San Francisco State University. Bernadette holds a BS in Biology from Syracuse University and a Master's degree in journalism from UC Berkeley.
Recent posts
-
You may take a bit of convincing to send a few dollars to filmmaker Denver Jackson, who’s seeking funds to complete his animated short “Cloudrise” through the crowdfunding site... Read more »
-
One big East Coast pharmaceutical firm abandoned work on a hepatitis C drug this week, while another shuttered a young company that had cost it $720 million to acquire. But new... Read more »
-
As flashy new entries piled into the race to create an injection-free hepatitis C drug about a year ago, Xconomy’s national biotech editor, Luke Timmerman, likened the contest to the Daytona... Read more »
-
The small private company Protein Sciences skirted bankruptcy, fought off a hostile takeover bid, spent three years angling for a sorely-needed government contract, and survived a four-year dialogue with the FDA... Read more »
-
New Jersey life sciences companies grabbed the spotlight this week as they raised money, joined with partners, and made new hires. Merck’s research division will have a new leader as a... Read more »
-
Another act in a stark boardroom drama unfolded this week for a public pharmaceutical company in New Jersey, but brighter stories took center stage in the Massachusetts biomedical arena.
—A sweeping... Read more »
-
Discoveries at the Yale School of Medicine are helping nearby Kolltan Pharmaceuticals in New Haven, CT, to try to keep cancer drugs working by eliminating the resistance that patients often develop... Read more »
-
Me-too drugs, knockoffs, copycats, retreads—they’re all names for new pharmaceuticals patterned after drugs already proven to work. The number of such labels alone signals the type of passionate commentary surrounding these... Read more »
-
The symbiotic ties between industry and university scientists were a big theme this week in East Coast news. Some top academic researchers became instant millionaires as tech moguls honored their biomedical... Read more »
-
Genome sequencing will be a routine diagnostic test for patients at the new Institute for Precision Medicine in New York City, a joint project of the Weill Cornell Medical College and... Read more »
-
Companies in the life sciences centers around Boston and New York made news this week with movement on cancer drug programs and efforts to create therapies by influencing the immune system.... Read more »
-
Supporters of New York City’s rising health IT sector are poring over scores of applications this week for $100,000 city grants to help young companies test-drive their health tech products by... Read more »
-
Many people steer their social lives from a single online dashboard, such as Facebook. Entrepreneur Girish Navani is betting that people will also want to use a densely connected Web platform... Read more »
-
Celgene of Summit, NJ, received some good news late Friday from the FDA, while Boston-area companies large and small made out well during the week, as partnerships were born and reformed.... Read more »
-
Hyperion Therapeutics (NASDAQ: HPTX) has weathered some setbacks on the way to its first drug approval, which came from the FDA last week. But many a life sciences startup would... Read more »
-
New York drug giant Pfizer is again responding to allegations that its former blockbuster drug Zoloft is an ineffective product that reaped billions of dollars by dint of aggressive marketing.
A... Read more »
-
California’s stem cell research funding agency has been shifting gears, and California entrepreneurs stand to benefit. The California Institute for Regenerative Medicine (CIRM) plans to spend hundreds of millions of dollars... Read more »
-
Veteran neuroscientist Corey Goodman says young life science entrepreneurs who want to launch startups often ask him for advice. Those aspiring biotechnology leaders might be surprised by what they hear from... Read more »
-
At the annual health care conference run by JP Morgan in San Francisco this week, and at satellite events surrounding it every year, hundreds of biotechnology companies showcased their work to... Read more »
-
“The whole is greater than the sum of its parts,” goes the famous quote attributed to Aristotle. But biotechnology company Elan didn’t see it that way when it split up its... Read more »
Page 2 of 3 « previous page · next page »
